
    
      First, the investigators will document exposure to ceftriaxone in plasma and epithelial
      lining fluid.

      Second, the investigators will try to identify risk factors for not attaining PK/PD target.
      Based on significant predictors for target non attainment a predictive dosing algorithm will
      be constructed.

      Finally in a small subset of ECMO patients PK exposure will be explored.
    
  